Human Genome Sciences, Inc. (HGSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steven Rachbach who wrote (1104)	8/27/2009 8:00:08 AM
From: kenhott	Read Replies (1) of 1127

The darapladib trial is a blinded trial. So GSK would only see the blended data till the very end. If there were planned interim reviews, GSK would not get efficacy data from these interim looks, just a go/nogo/stop kind of a answer. If the trial is a home run, the board would stop the trial early due to positive efficacy but that would be a long shot. Good luck.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next